JP7317038B2 - がん治療に使用するためのポリ(アルキルシアノアクリレート)ナノ粒子 - Google Patents
がん治療に使用するためのポリ(アルキルシアノアクリレート)ナノ粒子 Download PDFInfo
- Publication number
- JP7317038B2 JP7317038B2 JP2020552260A JP2020552260A JP7317038B2 JP 7317038 B2 JP7317038 B2 JP 7317038B2 JP 2020552260 A JP2020552260 A JP 2020552260A JP 2020552260 A JP2020552260 A JP 2020552260A JP 7317038 B2 JP7317038 B2 JP 7317038B2
- Authority
- JP
- Japan
- Prior art keywords
- cbz
- pebca
- nps
- drug delivery
- delivery system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO20180429 | 2018-03-27 | ||
| NO20180429 | 2018-03-27 | ||
| PCT/EP2019/057678 WO2019185685A1 (en) | 2018-03-27 | 2019-03-27 | Poly (alkyl cyanoacrylate) nanoparticles for use in treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021519323A JP2021519323A (ja) | 2021-08-10 |
| JP7317038B2 true JP7317038B2 (ja) | 2023-07-28 |
Family
ID=66049182
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020552260A Active JP7317038B2 (ja) | 2018-03-27 | 2019-03-27 | がん治療に使用するためのポリ(アルキルシアノアクリレート)ナノ粒子 |
| JP2021560300A Active JP7550167B2 (ja) | 2018-03-27 | 2019-09-26 | がんの治療に使用するためのポリ(アルキルシアノアクリレート)ナノ粒子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021560300A Active JP7550167B2 (ja) | 2018-03-27 | 2019-09-26 | がんの治療に使用するためのポリ(アルキルシアノアクリレート)ナノ粒子 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20210113482A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3773471A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7317038B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN111989087A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019437385B2 (cg-RX-API-DMAC7.html) |
| BR (2) | BR112020019452A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3134923A1 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2019185685A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12433846B2 (en) | 2019-03-27 | 2025-10-07 | Sintef Tto As | Drug delivery system for treatment of cancer |
| CN111989087A (zh) | 2018-03-27 | 2020-11-24 | 新泰福托特股份有限公司 | 用于治疗癌症的聚(氰基丙烯酸烷基酯)纳米颗粒 |
| JP7461932B2 (ja) * | 2018-08-23 | 2024-04-04 | シンテフ ティーティーオー エイエス | ナノ粒子 |
| KR20230031188A (ko) * | 2020-02-26 | 2023-03-07 | 바이오써젠 에이에스 | 치료적 폴리엔 마크롤리드의 제약 조성물 및 그의 사용 방법 |
| GB202501169D0 (en) | 2025-01-27 | 2025-03-12 | Sintef Tto As | Methods of producing polymeric particles |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009541462A (ja) | 2006-07-04 | 2009-11-26 | ナノデル テクノロジーズ ゲーエムベーハー | 2工程ミニエマルジョン法 |
| JP2016520606A (ja) | 2013-05-28 | 2016-07-14 | シンテフ ティーティーオー アクティーゼルスカブ | ステルスナノ粒子を調製するためのプロセス |
| CN107115532A (zh) | 2016-02-24 | 2017-09-01 | 首都医科大学宣武医院 | 一种双重修饰聚氰基丙烯酸正丁酯纳米粒、其制备方法及用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2872703B1 (fr) | 2004-07-07 | 2006-10-06 | Ethypharm Sa | Nanoparticules polymeriques composites |
| JP2008542293A (ja) | 2005-05-23 | 2008-11-27 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション | 超音波増強ナノ粒子媒介性薬物送達のためのエコー形成性マイクロバブルおよびマイクロエマルジョン |
| US8679539B2 (en) * | 2007-01-31 | 2014-03-25 | Tong Shen Enterprise Co., Ltd. | Drug-loaded poly (alkyl-cyanoacrylate) nanoparticles and process for the preparation thereof |
| FR2921660B1 (fr) | 2007-10-01 | 2015-09-25 | Centre Nat Rech Scient | Nanoparticules hybrides organiques inorganiques a base de carboxylates de fer. |
| EP2153821A1 (en) * | 2008-08-06 | 2010-02-17 | BioAlliance Pharma | Oral formulations of camptothecin derivatives |
| ES2424476T3 (es) | 2011-03-31 | 2013-10-02 | Bioalliance Pharma | Nanopartículas cargadas con fármaco antitumoral quimioterápico |
| US20150343079A1 (en) | 2012-10-25 | 2015-12-03 | Sogang University Research Foundation | Ultrasound contrast agent with nanoparticles including drug and method for preparing the same |
| US10391185B2 (en) | 2014-11-26 | 2019-08-27 | Fujifilm Visualsonics, Inc. | Multimodal ultrasound and photoacoustic contrast agent based on polymeric microparticles |
| WO2016134115A1 (en) | 2015-02-20 | 2016-08-25 | Trustees Of Boston University | Theranostic compositions and uses thereof |
| EP3316871A4 (en) * | 2015-06-30 | 2019-02-20 | The Trustees of Columbia University in the City of New York | TALKED COMPOSITION AND USES THEREOF |
| US20170071866A1 (en) * | 2015-09-14 | 2017-03-16 | Onxeo S.A. | Nanoparticles loaded with active ingredients, their process of preparation, and their uses |
| WO2017046037A1 (en) * | 2015-09-14 | 2017-03-23 | Onxeo | Nanoparticles loaded with active ingredients, their process of preparation and their uses |
| US10980826B2 (en) * | 2015-11-06 | 2021-04-20 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| KR102803158B1 (ko) * | 2015-12-02 | 2025-05-08 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도 |
| KR20170133257A (ko) | 2016-05-24 | 2017-12-05 | 한양대학교 산학협력단 | 항암제 함유 나노입자를 포함하는 뇌질환 치료를 위한 비강 투여용 약제학적 조성물 |
| EP3518900A1 (en) | 2016-09-29 | 2019-08-07 | Sintef TTO AS | A new drug delivery system for treatment of disease |
| NO342271B1 (en) | 2016-09-29 | 2018-04-30 | Sintef Tto As | A new drug delivery system for treatment of cancer |
| CN111989087A (zh) * | 2018-03-27 | 2020-11-24 | 新泰福托特股份有限公司 | 用于治疗癌症的聚(氰基丙烯酸烷基酯)纳米颗粒 |
| US12433846B2 (en) | 2019-03-27 | 2025-10-07 | Sintef Tto As | Drug delivery system for treatment of cancer |
-
2019
- 2019-03-27 CN CN201980022079.9A patent/CN111989087A/zh active Pending
- 2019-03-27 EP EP19715854.6A patent/EP3773471A1/en active Pending
- 2019-03-27 WO PCT/EP2019/057678 patent/WO2019185685A1/en not_active Ceased
- 2019-03-27 US US17/041,094 patent/US20210113482A1/en active Pending
- 2019-03-27 JP JP2020552260A patent/JP7317038B2/ja active Active
- 2019-03-27 BR BR112020019452-2A patent/BR112020019452A2/pt unknown
- 2019-03-27 US US16/366,596 patent/US11806330B2/en active Active
- 2019-09-26 AU AU2019437385A patent/AU2019437385B2/en active Active
- 2019-09-26 BR BR112021019003A patent/BR112021019003A2/pt not_active Application Discontinuation
- 2019-09-26 CA CA3134923A patent/CA3134923A1/en active Pending
- 2019-09-26 WO PCT/EP2019/076121 patent/WO2020192950A1/en not_active Ceased
- 2019-09-26 JP JP2021560300A patent/JP7550167B2/ja active Active
- 2019-09-26 EP EP19779462.1A patent/EP3946253A1/en active Pending
- 2019-09-26 CN CN201980096306.2A patent/CN113840594A/zh active Pending
- 2019-11-12 US US16/583,687 patent/US20200061019A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009541462A (ja) | 2006-07-04 | 2009-11-26 | ナノデル テクノロジーズ ゲーエムベーハー | 2工程ミニエマルジョン法 |
| JP2016520606A (ja) | 2013-05-28 | 2016-07-14 | シンテフ ティーティーオー アクティーゼルスカブ | ステルスナノ粒子を調製するためのプロセス |
| CN107115532A (zh) | 2016-02-24 | 2017-09-01 | 首都医科大学宣武医院 | 一种双重修饰聚氰基丙烯酸正丁酯纳米粒、其制备方法及用途 |
Non-Patent Citations (2)
| Title |
|---|
| Bulg. J. Chem.,2012年,Vol. 1, No. 2,pp. 61-73 |
| Ultrasound in Med. & Biol.,2017年,Vol. 43, No. 11,pp. 2651-2669 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020019452A2 (pt) | 2021-01-05 |
| JP7550167B2 (ja) | 2024-09-12 |
| US20200061019A1 (en) | 2020-02-27 |
| EP3946253A1 (en) | 2022-02-09 |
| CN111989087A (zh) | 2020-11-24 |
| WO2019185685A1 (en) | 2019-10-03 |
| US11806330B2 (en) | 2023-11-07 |
| EP3773471A1 (en) | 2021-02-17 |
| US20190298682A1 (en) | 2019-10-03 |
| AU2019437385A1 (en) | 2021-11-04 |
| AU2019437385B2 (en) | 2025-04-10 |
| JP2022527858A (ja) | 2022-06-06 |
| WO2020192950A1 (en) | 2020-10-01 |
| US20210113482A1 (en) | 2021-04-22 |
| CA3134923A1 (en) | 2020-10-01 |
| CN113840594A (zh) | 2021-12-24 |
| JP2021519323A (ja) | 2021-08-10 |
| BR112021019003A2 (pt) | 2021-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fusser et al. | Cabazitaxel-loaded Poly (2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft | |
| Albuquerque et al. | pH-responsive polymersome-mediated delivery of doxorubicin into tumor sites enhances the therapeutic efficacy and reduces cardiotoxic effects | |
| Chen et al. | Anti prostate cancer therapy: aptamer-functionalized, curcumin and cabazitaxel co-delivered, tumor targeted lipid-polymer hybrid nanoparticles | |
| Yang et al. | Estrone-modified pH-sensitive glycol chitosan nanoparticles for drug delivery in breast cancer | |
| Song et al. | Erythrocyte-biomimetic nanosystems to improve antitumor effects of paclitaxel on epithelial cancers | |
| Liu et al. | Enhanced antitumor efficacy, biodistribution and penetration of docetaxel-loaded biodegradable nanoparticles | |
| Cho et al. | Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin | |
| Danhier et al. | Paclitaxel-loaded micelles enhance transvascular permeability and retention of nanomedicines in tumors | |
| US20210113482A1 (en) | Poly (Alkyl Cyanoacrylate) Nanoparticles for Use in Treatment of Cancer | |
| Sun et al. | Enhanced antitumor efficacy of vitamin E TPGS-emulsified PLGA nanoparticles for delivery of paclitaxel | |
| Yuan et al. | A novel self‐assembly albumin nanocarrier for reducing doxorubicin‐mediated cardiotoxicity | |
| CN108938594B (zh) | 一种药物复合物及其制备方法与应用 | |
| Zhang et al. | Multifunctional polyethylene glycol (PEG)-poly (lactic-co-glycolic acid)(PLGA)-based nanoparticles loading doxorubicin and tetrahydrocurcumin for combined chemoradiotherapy of glioma | |
| JP7164205B2 (ja) | キナ酸修飾ナノ粒子およびその使用 | |
| Hyldbakk et al. | Intraperitoneal administration of cabazitaxel-loaded nanoparticles in peritoneal metastasis models | |
| Wang et al. | A sphingolipid-derived paclitaxel nanovesicle enhances efficacy of combination therapies in triple-negative breast cancer and pancreatic cancer | |
| Zhang et al. | Tumor-targeting micelles based on linear–dendritic PEG–PTX8 conjugate for triple negative breast cancer therapy | |
| Zhu et al. | Delivery of acetylthevetin B, an antitumor cardiac glycoside, using polymeric micelles for enhanced therapeutic efficacy against lung cancer cells | |
| Kazemi et al. | In vitro and in vivo evaluation of novel DTX-loaded multifunctional heparin-based polymeric micelles targeting folate receptors and endosomes | |
| Enteshari et al. | Antitumor activity of raloxifene-targeted poly (styrene maleic acid)-poly (amide-ether-ester-imide) co-polymeric nanomicelles loaded with docetaxel in breast cancer-bearing mice | |
| Jin et al. | Improved anti-tumor efficiency against prostate cancer by docetaxel-loaded PEG-PCL micelles | |
| Santini et al. | Intravenous and intratumoral injection of Pluronic P94: The effect of administration route on biodistribution and tumor retention | |
| Zhao et al. | A’stealth’gene delivery system targeting hepatic stellate cells for the treatment of liver fibrosis | |
| Han et al. | Inhibition of C6 glioma in vivo by combination chemotherapy of implantation of polymer wafer and intracarotid perfusion of transferrin-decorated nanoparticles | |
| US12433846B2 (en) | Drug delivery system for treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220325 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230125 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230131 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230426 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230704 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230718 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7317038 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |